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We report that NTRK2, the gene encoding for the TrkB receptor, can regulate APP metabolism, speciﬁcally AICD levels. Using the
human neuroblastoma cell line SH-SY5Y, we characterized the eﬀect of three TrkB isoforms (FL, SHC, T) on APP metabolism by
knockdown and overexpression. We found that TrkB FL increases AICD-mediated transcription and APP levels while it decreases
sAPPlevels.TheseeﬀectsweremainlymediatedbythetyrosinekinaseactivityofthereceptorandpartiallybythePLC-γ-andSHC-
binding sites. The TrkB T truncated isoform did not have signiﬁcant eﬀects on APP metabolism when transfected by itself, while
the TrkB SHC decreased AICD-mediated transcription. TrkB T abolished TrkB FL eﬀects on APP metabolism when cotransfected
with it while TrkB SHC cotransfected with TrkB FL still showed increased APP levels. In conclusion, we demonstrated that TrkB
isoforms have diﬀerential eﬀects on APP metabolism.
1.Introduction
Alzheimer’s Disease (AD) is a neurodegenerative disorder
that will aﬀect 15 million people in USA alone in the next
ten years [1, 2]. The most common form of the disease is
the late onset form (LOAD) that aﬀects people older than
65. LOAD is caused by a complex interaction of risk factors
including age, genetics, and environmental factors, such as
level of education, diet, and physical activity [3–7].
The accumulation of Aβ, a neurotoxic product of
amyloid precursor protein (APP) cleavage, is central to
AD pathogenesis [8–10]. This accumulation causes synaptic
dysfunctionandeventuallyneuronaldeath[9,10].Therefore
proteins that aﬀect APP metabolism and synaptic function
are likely to be important in AD pathogenesis.
TrkB is a member of the tyrosine kinase receptor family
(Trk). TrkB speciﬁcally binds Brain-Derived Neurotrophic
Factor (BDNF). The neurotrophin receptors (TrkA, TrkB,
and TrkC) are important in neuronal development and
synaptic function [11, 12]. Levels of TrkA, TrkB, and TrkC,
butnotp75NTR,aredownregulatedinADbrainsamples[13].
Trk downregulation has been proposed as a biomarker of AD
progression since Trk mRNA levels correlate with the degree
of cognitive impairment [13].
Further evidence for a role of TrkB in AD is the
fact that TrkB can modulate APP levels and proteolysis.
Expression of the longest TrkB isoform, full-length TrkB
(TrkB FL), can increase APP promoter transcription and
promotes accumulation of sAPP-α [14–17]. Conversely, Aβ
hasbeenfoundtoreduceTrkBFL/BDNFlevelsandtoimpair
TrkB-mediated signaling [18–21]. These results suggest a
dynamic interaction between TrkB/BDNF signaling and APP
metabolism.
Interestingly, knockdown of another splice variant of
TrkB, truncated TrkB (TrkB T) in a mouse model of Down
syndrome rescued neuronal death [22]. Conversely, mice
overexpressing TrkB T display synaptic dysfunction and
long-term potentiation defects [23].
The gene encoding TrkB, NTRK2,i sl o c a t e do nc h r o m o -
some 9, speciﬁcally 9q22. This region has been genetically
linked to AD [24, 25]. Despite the experimental evidence
functionally linking TrkB signaling to APP metabolism and
synaptic function, case-control and genomewide association
studies of NTRK2 single nucleotide polymorphisms (SNPs)2 International Journal of Alzheimer’s Disease
found no signiﬁcant association with AD [25–30]. One
family-basedstudydidobservegeneticassociationofNTRK2
haplotypes with AD [26].
Three major splice variants of TrkB are expressed in
neurons, TrkB FL, TrkB SHC, and TrkB T. We hypothesized
that these diﬀerent TrkB isoforms diﬀerentially aﬀect APP
metabolism and could play a role in the pathogenesis of AD.
The aim of this work was to test this hypothesis.
The three TrkB splicing isoforms we investigated share
an extracellular BDNF binding domain and diﬀer in their
cytoplasmic-domain (Figure 1)[ 31]. Two splice variants
encode full-length receptors, TrkB full-length (FL), that
contain a tyrosine kinase domain, an SHC-binding domain
andaPLC-γ-bindingdomainintheintracellularportion[32,
33]. Two isoforms encode shorter receptors, TrkB SHC, that
contain only an SHC-binding domain, and the remaining
isoform is a truncated receptor, TrkB T, that does not
have any known intracellular functional domain (Figure 1).
Recently, isoforms diﬀering in the extracellular domain have
also been identiﬁed [34].
We used a previously described cell-based functional
screen [35] to identify putative APP metabolism regulators.
We found that NTRK2 knockdown altered both AICD-
mediated luciferase activity and APP full-length levels. To
characterize the role of TrkB FL and truncated isoforms we
knocked down and overexpressed the isoforms in an SH-
SY5Y neuroblastoma cell line overexpressing APP as a fusion
protein with the yeast transcription factor Gal-4 [35]. We
then measured APP FL levels and proteolytic products using
Western blots and luciferase assays.
Our results demonstrate for the ﬁrst time that TrkB
isoforms diﬀerentially aﬀect APP metabolism. Speciﬁcally,
overexpression of TrkB FL increases AICD-Gal4-mediated
luciferase activity. While overexpression of TrkB T does
not alter the luciferase activity and TrkB SHC decreases
the luciferase activity compared to control. We determined
that the tyrosine kinase and PLC-γ functional domains
contribute to the observed TrkB FL-mediated eﬀects. We
also found that the SHC-binding site contributed to the
observed TrkB-SHC-mediated eﬀects. BDNF stimulation of
the exogenously expressed TrkB receptors ampliﬁed the
APP metabolism eﬀects and cotransfection of the TrkB-
truncated isoforms with TrkB FL altered the eﬀects on APP
metabolism.
2.MaterialsandMethods
2.1. Constructs and Site-Directed-Mutagenesis. Four shRNA-
containing plasmids speciﬁc for NTRK2 were obtained
from the pSM2 retroviral Library of the Drexel RNAi
Resource Center purchased from Open Biosystems. The
constructs ID numbers are NTRK2.1: 1920; NTRK2.2: 2295;
NTRK2.3: 29734; NTRK2.4: 30795. We also used APP
(ID 39147) and luciferase targeting shRNA (RHS1705) as
positive controls and a scrambled shRNA sequence (non-
silencing, NS, RHS1707) as a negative control. The TrkB
full-length and truncated GFP fusion constructs and the
GFP-F control overexpression plasmid were kindly donated
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Figure 1: TrkB isoforms structure and functional domains. The
extracellular portion of the receptor is conserved. The intracellular
domain diﬀers among the isoforms. TrkB FL contains a tyrosine
kinase domain, a SHC-binding domain, and a PLC-γ-binding
domain. TrkB SHC contains a SHC-binding domain and TrkB T
does not have any functional domain.
by Dr. Eero Castren (University of Helsinki, Finland) and
werepreviouslydescribed[36,37].Site-directedmutagenesis
(Stratagene, Quikchange mutagenesis kit) was utilized to
generate point mutants on the TrkB full-length receptor
functional domains. Mutagenesis was carried out according
to manufacturer’s instructions and the primers employed
are reported in Table 1 (the bolded sequences represent
the mutations/insertion). The mutant amino acid indicated
refers to the amino acidic sequence of TrkB. Therefore TrkB
FLK571Mindicatesthetyrosinekinasedeadreceptorsinceit
is mutated on the ATP-binding site; TrkB FL Y515F indicates
the receptor mutated on the SHC-binding site; TrkB FL
Y816F indicates the receptor mutated on the PLC-γ-binding
site [38]. Note that in some literature the TrkB mutants are
referred to with the numbering of the amino acidic sequence
of TrkA, the NGF receptor, that has functional sites in
common with TrkB and therefore are referred to as K560M,
Y490F and Y785F respectively [32, 33]. TrkB SHC indicates
the other human truncated isoform (isoform d and e, NCBI
Gene NM 001018064·2a n dN M001018066·2). TrkB SHC
was obtained by insertion of the exon 19 followed by a STOP
codon after the SHC-binding site on the TrkB FL constructs.
AfterobtainingtheTrkBSHCisoformbyinsertion,theSHC-
binding site was mutated on that isoforms using the same
primer sequence employed for the TrkB FL mutant on the
SHC-binding site (TrkB Y515F).
Successful mutations were identiﬁed by sequencing. One
clone per construct was transformed in E. coli (DH5-α
competent cells, InVitrogen). Transformed bacteria were
selected on 100μg/mL ampicillin LB-agar plates and liquid
cultures were grown overnight at 37◦C. Bacterial cultures
were miniprepped (MiniPrep Kit, Quiagen) and used for
transfection after DNA quantiﬁcation.
2.2. Cell Culture and Transfection. SH-SY5Y cells stably
transfected with UAS-Luciferase and APP-Gal4 describedInternational Journal of Alzheimer’s Disease 3
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Figure 2: AICD-mediated Luciferase activity in SH-SY5Y-APP-Gal4 cells with TrkB knockdown or TrkB overexpression. (a) shRNA-
mediated NTRK2 knock-down. Luciferase activity is decreased by NTRK2 knockdown compared to nonsilencing control (P = .03). There is
no signiﬁcant diﬀerence between luciferase activity in NTRK2 knockdown and APP knockdown cells. shRNA constructs: negative control,
NS,scrambledshRNAsequence;positivecontrol,APP,shRNAtargetingAPP;experimentalshRNA,NTRK2.1-3,shRNAconstructstargeting
allTrkBisoforms.Theexperimentwasrepeatedfourtimesindependentlyandeachtimewithsixreplicates.(b)TrkBisoformoverexpression.
Luciferase activity was not altered by TrkB T compared to GFP control. Luciferase activity was increased by TrkB FL (P = .01) and decreased
by TrkB SHC (P = .01) compared to a GFP-control vector. The experiment was repeated 3 to 6 times independently with 6 replicates
each time. The y-axis represents the arbitrary light units of ﬁreﬂy luciferase normalized to cell number (a) or transfection eﬃciency (b).
Error bars = SEM. Statistical analysis: ANOVA and Students t-test with Bonferroni correction where applicable.
Table 1: Primer sequences used to obtain the point mutations and the sequence insertion on the TrkB FL receptor. The mutated bases are
represented in bold.
Primers Sequence 5  to 3 
TrkB.Y490F.F GTCATTGAAAACCCCCAGTTCTTCGGTATCACCAACAG
TrkB.Y490F.R CTGTTGGTGATACCGAAGAACTGGGGGTTTTCAATGAC
TrkB.Y816F.F GCGTCGCCCGTCTTCCTGGACATCCTAG
TrkB.Y816F.R CGCAGCGGGCAGAAGGACCTGTAGGATC
TrkB.Shc.F CTCAAGCCGGACACATGGCCCAGAGGTTCCCCCAAGACCGCCTGATAGTAATTTGTTCAGCACATC
TrkB.Shc.R GATGTGCTGAACAAATTACTATCAGGCGGTCTTGGGGGAACCTCTGGGCCATGTGTCCGGCTTGAG
TrkB K560M.F GGTGGCCGTGATGACGCTGAAGG
TrkB K560M.R CCTTCAGCGTCATCACGGCCACC
TrkB.SHC GTCATTGAAAACCCCCAGTTCTTCGGTATCACCAACAG
TrkB.SHC CTGTTGGTGATACCGAAGAACTGGGGGTTTTCAATGAC
before [35] were maintained in DMEM (Gibco) sup-
plemented with 10% FBS, penicillin streptomycin and
200μg/mL G418 (Gibco).
To assess the eﬀects of TrkB knockdown or overex-
pression on AICD-Gal4 mediated luciferase we used the
following transfection protocol previously described [35].
Brieﬂy, one day before transfection cells were plated in 96-
wells plates at approximately 40–50% conﬂuency. The day of
transfection media was removed from the cells and replaced
with transfection media: 100μLo fs e r u mf r e eD M E M
media containing 2μg/well Arrest-In (Open Biosystems) and
0.2μg/well plasmid DNA. The pSM2 plasmids referred to
as NTRK2.1 through 4 were transfected in the cells. Cells
were also transfected with shRNA targeting APP, luciferase
and a control shRNA that contains a scrambled sequence
that does not target any human gene. In addition a mock
transfection, containing only Arrest-In was performed to
control for selection eﬀectiveness. 6 replicate wells per
shRNA constructs and mock control transfection were set
upforeachindependentexperiment.Thetransfectionmedia
was left on the cells for 8 hours and then replaced with
complete media. 48 hours after transfection, transfected
cells were selected with 4μg/mL puromycin (Sigma) in 10%
FBS DMEM with 200μg/mL G418. Puromycin selection was
used to preserve transiently transfected cells. The media
w a sc h a n g e de v e r y4 8h o u r sa n dc e l ld e a t hw a sm o n i t o r e d
and compared to the mock-transfected control. Once all the
cells in the mock control wells were dead, surviving cells in
the shRNA transfected wells were split and transferred to
another 96-well plate and a 24-well plate. Cell lysates were
collected from 60–80% conﬂuent 96-wells 11–13 days after
transfection in 100μL Glo Lysis Buﬀer per well (Promega).
Lysates were used immediately after collection or frozen
prior to performing Steady Glo luciferase assays (Promega).
The luciferase assays were performed as per manufacturer’s
instructions. shRNA-mediated knockdown eﬀectiveness was4 International Journal of Alzheimer’s Disease
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Figure 3: Mutation of TrkB FL intracellular functional domains
changes the eﬀect on AICD-mediated luciferase activity. (a) The
TrkB SHC isoform signiﬁcantly decreases luciferase activity when
compared to TrkB T (P = .001). The TrkB SHC Y515F mutant,
unable to bind SHC, increases luciferase activity compared to TrkB
SHC (P<. 001) and does not signiﬁcantly alter luciferase activity
compared to TrkB T (P = .1). (b) TrkB Y515F (no SHC-binding)
does not signiﬁcantly alter luciferase activity compared to TrkB FL.
TrkB K571M with an inactive tyrosine kinase domain signiﬁcantly
decreases luciferase activity compared to TrkB FL (P = .0006); TrkB
Y515F/K571M signiﬁcantly decreases luciferase activity compared
to TrkB FL (P = .002) but not to a greater extent of TrkB
K571M. TrkB Y816F that does not bind PLC-γ also signiﬁcantly
decreases luciferase activity compared to TrkB FL (P = .0002). 4–8
independent experiments with 6 replicates each, error bars SEM. 4–
6 independent experiments with 6 replicates each, error bars SEM.
Statistical analysis: Student’s t-test with Bonferroni correction.
monitored by comparing the luciferase signal of the non-
silencing control shRNA with the APP targeting shRNA.
After assessing successful knock-down, luciferase data for
the experimental shRNA targeting NTRK2 was collected and
analyzed. In parallel, 24-well plates and 12-well plates were
seededwiththesamecellsthathadbeenassayedforluciferase
signal and collected for Western Blot analysis.
The same transfection procedure was followed for the
overexpression experiments, but lysates were collected 48
hours aftertransfectionand transfectioneﬃciency was mon-
itored by ﬂuorescence microscopy, no antibiotic selection
was performed in this case.
2.3. Western Blotting Procedures. Conditioned media was
collected from the cells (48 hours after transfection) in
eppendorf tubes and centrifuged at 14,000rpm for 10
minutes at 4◦C (Beckman Coulter, Microfuge 22R). The
resulting supernatant was collected and 142μLw e r em i x e d
with 33μL of 4X Reducing loading buﬀer (InVitrogen)
supplementedwith0.4% β-mercaptoethanol(Sigma).These
samples were heated at 70◦C for 10 minutes. The remaining
conditioned media was stored at −20◦C for later Western
Blot analysis.
Whole cell lysates were collected (48 hours after trans-
fection) by lysing the cells with ice-cold radio immuno-
precipitation (RIPA) buﬀer (150mM NaCl, 1% NP40,
0.5% DOC, 1%SDS, 50mMTris, pH 8.0) supplemented
with Halt cocktail of protease and phosphatase inhibitors
(ThermoScientiﬁc). Cell lysates were sonicated in an ice-
cold water bath sonicator for 6 minutes then centrifuged 20
minutes at 4◦C at 14,000rpm. The resulting supernatants
were collected and protein concentration measured with
a BCA protein concentration kit (Pierce) according to
manufacturer’s instructions.
Western blot samples were prepared at a ﬁnal concentra-
tion of 1-2μg/μL in 4X reducing loading buﬀer (InVitrogen)
a n dh e a t e da t7 0 ◦C for 10 minutes. 15–25μgo ft o t a l
protein/well were separated on 4–12% Tris-Glycine midi gels
(InVitrogen) in MES-SDS running buﬀer (InVitrogen) and
run at 190mVolts for 45 minutes. The separated proteins
were transferred to PVDF FL membranes (Millipore) in a
Semi-Dry transfer apparatus (AA Hoefer TE77X) for 3 hours
at 125 milli Amp per gel.
M e m b r a n e sw e r eb l o c k e do n eh o u ra tr o o mt e m p e r a t u r e
using Licor blocking buﬀer then probed overnight with
primary antibodies diluted in Licor blocking buﬀer at 4
or 25◦C. Membranes were then washed for 5 minutes 4
times with 0.1% Tween (Sigma) in PBS. One last wash
was performed with PBS to rinse oﬀ the detergent. After
washing, membranes were incubated in the dark with the
appropriate secondary antibody IRDye (Licor) diluted in
Licor blocking buﬀer for one hour. Again membranes were
washed as above and ﬁnally rinsed with PBS. Membranes
were scanned on an Odyssey InfraRed scanner (Licor) at
appropriate intensities and images acquired. Band intensities
were quantiﬁed with the provided in-built software (Licor)
and always normalized to the actin loading control. When
conditioned media was analyzed the signals were normalized
to the protein concentration of the corresponding lysates.
2.4. Antibodies. Detection of TrkB-GFP tagged constructs
utilized mouse anti-GFP antibody (1:1000, Living Colors,
Clontech); detection of APP full-length and C-terminal frag-
ments utilized A8717 rabbit antibody (1:2000, Rb, Sigma);
detection of sAPP 22C11 utilized mouse antibody (1:1000,
Millipore); detection of sAPP-α 6E10 utilized mouse anti-
body (1:1000, Covance); detection of actin A5441 uti-
lized mouse antibody (1:15,000, Sigma). The secondary
antibodies: IRDye700 anti-mouse antibody (1:15,000) and
IRDye800 anti-rabbit antibody (1:15,000) were obtained
from by Licor.
3. Results
3.1. NTRK2 Knockdown Decreases AICD-Mediated Luciferase
Activity. We applied our functional screening method [35]International Journal of Alzheimer’s Disease 5
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Figure 4: NTRK2 knockdown decreases APP full-length levels. (a) Representative Western Blot of APP full-length and actin as a loading
control in lysates from cells transfected with shRNA constructs targeting APP, luciferase (LUC), NTRK2 and a negative, nonsilencing
(NS), control. (b) Average quantiﬁcation of APP full-length levels from four independent Western Blot analysis conducted on independent
transfections.WithineachtransfectionAPPFLdensitometrywasnormalizedtotheAPPFLdensitometryofthecelllysateobtainedfromcells
transfected with CTRL shRNA. A statistically signiﬁcant diﬀerence was observed between CTRL and the APP or NTRK2 shRNA targeting
constructs (P<. 05). The experiment was repeated four times independently with three replicates each, error bars indicate SEM. Statistical
analysis: ANOVA.
to all the genes in the linkage region on chromosome 9 that
displays a high likelihood of disease score for AD [39]. This
screening is conducted in SH-SY5Y cells stably transfected
with a luciferase reporter driven by the yeast UAS promoter
and APP fused to Gal4. When APP is cleaved by the secre-
tases, the AICD-Gal4 domain is released and can activate the
transcription of the luciferase reporter. Variations in AICD-
mediated luciferase activity are measured. Since changes
in AICD-mediated luciferase activity can occur through a
variety of mechanisms aﬀecting APP, this is an eﬀective and
general way of identifying regulators of APP metabolism
[35]. We targeted NTRK2 with 4 diﬀerent shRNA constructs
(see supplementary Figures 1 and 2 in the supplementary
material available online at doi: 10.4061/2011/729382).
Three shRNAs targeted all the TrkB isoforms (NTRK2.1-
3) and one (NTRK2.4) targeted all the isoforms except the
TrkB T. We also transfected a nonsilencing scrambled shRNA
(NS) that does not target any human gene as a negative
control and a shRNA targeting APP as a positive control. Of
the four transfected constructs NTRK2.1-3 decreased AICD-
mediated luciferase to the same extent of the APP targeting
shRNAcomparedtotheNSshRNA(Figure 2(a)).Thefourth
construct, NTRK2.4 targeting all TrkB isoforms except TrkB
T,consistentlycausedcelldeath(datanotshown).Thisresult
suggests that NTRK2 can aﬀect APP metabolism and that the
isoforms have diﬀerent roles since downregulation of all the
isoforms except TrkB T was lethal. Therefore we investigated
the eﬀect of the single isoforms in the same experimental
model.
We transiently transfected individual TrkB isoform over-
expression constructs in the cells and measured AICD-
mediated luciferase activity. We found that there was no
diﬀerence in AICD-mediated luciferase activity between
TrkB T and the GFP-control, while TrkB FL signiﬁcantly
increased luciferase activity (P = .01) and TrkB SHC
signiﬁcantly decreased it (P = .01) (Figure 2(b)). These
results demonstrate that TrkB isoforms have diﬀerent eﬀects
on APP metabolism. Moreover, we show that there is a
diﬀerence between the isoforms TrkB SHC and TrkB T, even
though both isoforms lack the tyrosine kinase domain.
3.2. The Tyrosine Kinase and PLC-γ-Binding Domains of TrkB
FL and the SHC-Binding Domain on TrkB SHC Determine
the Eﬀe c to nA I C D - M e d i a t e dL u c i f e r a s eA c t i v i t y. TrkB T did
not alter AICD-mediated luciferase activity compared to the
GFP-F control, while TrkB SHC decreased it and TrkB FL
increased it. We hypothesized that the intracellular domains
of the TrkB SHC and TrkB FL are responsible for the eﬀects
observed. To determine which domain was responsible for
this eﬀect, we mutated each cytoplasmic functional domain
individually.
We generated a mutant of the TrkB SHC isoform that
cannot bind SHC (Y515F). We transfected this mutant and
the other TrkB wild-type isoforms, into SH-SY5Y-APP-Gal4
cells and measured AICD-mediated luciferase activity. We
observed that TrkB SHC Y515F (SHC-binding site mutant)
does not signiﬁcantly alter luciferase activity compared to
TrkB T but signiﬁcantly increased it compared to the TrkB
SHC wild-type isoform (P<. 001) (Figure 3(a)). Therefore,
disrupting the SHC-binding site on the TrkB SHC isoform
impairs its ability to decrease AICD-mediated luciferase
activity.
We then generated mutants in the three functional sites
of the TrkB FL. We mutated the SHC-binding site (Y515F)
to generate a mutant that cannot bind SHC [33]. Then we
mutatedtheATP-bindingsite(K571M)togenerateaTrkBFL
tyrosine kinase inactive receptor K571M [32, 33]. Similarly,
we disrupted the PLC-γ-binding site by introducing the
mutation Y816F. We also generated a double mutant that is
both tyrosine kinase inactive and does not bind SHC (TrkB
Y515F/K571M). We then transfected these TrkB FL mutant
constructs in SH-SY5Y-APP-Gal4 cells. We measured the
AICD-mediated luciferase activity and compared it to TrkB
FL wild-type (Figure 3(b)).6 International Journal of Alzheimer’s Disease
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Figure 5: TrkB isoform overexpression aﬀects APP FL levels and APP processing. (a) TrkB FL increases APP FL levels compared to TrkB
T( P = .03) and TrkB SHC isoforms (P = .008). 5 independent experiments in duplicate, error bars indicate SEM. (b) TrkB FL increases
AICD levels compared to TrkB T and TrkB SHC decreases AICD levels. (c) TrkB FL, TrkB T, and TrkB SHC do not alter C83 levels. Cells were
treated with L-685,485 to aid in C83-Gal4 visulaization (d) sAPP levels in conditioned media. TrkB FL signiﬁcantly decreases sAPP levels
compared to TrkB T (P = .003). The experiment was repeated four times independently in duplicate. Error bars indicate SEM. Statistical
analysis: Students t-test with Bonferroni correction.
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Figure 6: Short-term or long-term BDNF treatment of TrkB
isoforms transfected cells. APP full-length (FL) levels are increased
by a 10 minutes BDNF treatment of TrkB FL transfected cells while
a 24 hours treatment shows lower APP FL levels. TrkB T and TrkB
SHC transfected cells are not signiﬁcantly aﬀected by short term or
long-term BDNF treatment.
The TrkB Y515F mutant (preventing SHC-binding) did
not signiﬁcantly alter AICD-mediated luciferase activity
compared to TrkB FL (Figure 3(b)). The TrkB FL K571M
(tyrosine kinase inactive) signiﬁcantly decreased luciferase
activity compared to TrkB FL (P = .0006). TrkB FL Y816F,
(preventing PLC-γ-binding) also signiﬁcantly decreased
luciferase activity compared to TrkB FL (P = .0002).
The double mutant TrkB Y515F/K571M (preventing SHC-
binding and tyrosine kinase inactive) signiﬁcantly decreased
luciferase compared to TrkB FL (P = .002) but did not diﬀer
from the tyrosine kinase inactive TrkB K571M (Figure 2(a)).
In summary, TrkB FL overexpression increases AICD-
Gal4 mediated luciferase activity two-fold compared toInternational Journal of Alzheimer’s Disease 7
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Figure 7: Cotransfection of TrkB FL with isoforms and mutants alters the TrkB FL eﬀects on APP full-length. TrkB FL transfection increases
APP FL levels compared to when TrkB FL is cotransfected with TrkB T, TrkB SHC or TrkB K571M. APP FL levels did not signiﬁcantly diﬀer
between TrkB FL transfected cells and TrkB FL cotransfection with TrkB Y515F or TrkB Y816F. 24 hours BDNF treatment of cotransfected
cells did not signiﬁcantly alter APP FL levels compared to cotransfected but nontreated cells.
controls TrkB T (Figure 2(b)). The tyrosine kinase inactive
mutant receptor, TrkB K571M, the PLC-γ-binding site
mutant, and the TrkB SHC isoform mutated on the SHC-
binding sitealsocausea60–70% decreasein AICD-mediated
luciferase activity compared to the TrkB FL (Figures 3(a) and
3(b)). The TrkB SHC wild-type isoform causes an AICD-
mediated luciferase decrease of about 90% (Figure 2(b)).
3.3. NTRK2 Knockdown Decreases APP FL Levels. The
eﬀects we observe on AICD-mediated luciferase activity can
occur through many diﬀerent mechanisms: decreased APP
transcription, increased APP degradation, decreased APP
cleavage, destabilization of AICD, and traﬃcking that aﬀects
APP localization. Anything that decreases AICD levels will
be reﬂected in a decrease in luciferase activity. The most
immediate way of decreasing AICD levels is to decrease APP
levels. To determine if NTRK2 knockdown decreased APP
levels, we tested if APP levels were altered. We transfected
the NTRK2 targeting shRNA, a CTRL shRNA, and an APP
targeting shRNA as a positive control. As an additional
control we used shRNA targeting the luciferase gene: this
construct accounts for overexpression of shRNA that have to
be processed by the endogenous RNAi machinery. We then
measured APP protein levels by Western blot (Figure 4(a)).
We found that knockdown of all the TrkB splice variants
cause a signiﬁcant decrease in APP FL levels (P<. 05)
(Figure 4(b)) and we concluded that decreased APP levels
might be at least partially responsible for the observed
reduction in luciferase activity.
3.4. TrkB FL Overexpression Increases APP FL Levels and
AICD Gal4 Levels. Based on the previous knockdown
results, we then hypothesized that overexpression of TrkB
FL causes increased AICD-mediated luciferase activity by
increasing APP FL levels. We transfected the TrkB isoforms
in the cells, performed Western blot analysis and quantiﬁed
APP FL levels in cell lysates. Overexpression of TrkB FL
signiﬁcantly increased APP FL levels compared to TrkB T
(P = .03) and TrkB SHC (P = .008) (Figure 5(a)). There
was no diﬀerence in APP levels between TrkB T- and TrkB
SHC-transfected cells (Figure 5(a)).
We then veriﬁed that AICD-Gal4 levels in TrkB FL-
transfected cells correlated to the observed increase in
luciferase activity. AICD-Gal4 is the intracellular domain of
APP that is, generated by γ-secretase cleavage, translocates
to the nucleus and activates transcription. We found that,
as expected, TrkB FL displayed increased AICD-Gal4 levels
compared to TrkB T, but this diﬀerence was not statistically
signiﬁcant. Compared to TrkB T, TrkB SHC overexpression
resulted in a decrease in AICD-Gal4 levels, as expected, but
this diﬀerence was not statistically signiﬁcant (Figure 5(b)).
Interestingly, we consistently observed TrkB FL lower levels
compared to TrkB T and TrkB SHC in our Western blot
analysis (Figure 5(a)).
3.5. TrkB FL Overexpression Decreases sAPP Levels without
Altering C83 Levels. To assess changes in APP proteolysis
we measured APP C-terminal fragments (CTFs) and sAPP
levels upon TrkB transfection. CTFs include both C83 and
C99. C83 and C99 are generated by the cleavage of APP
by α-secretase and β-secretase, respectively. In our cell
line we measure C83-Gal4 and C99-Gal4 levels since APP
overexpressed is a fusion protein with Gal4. These fragments
are the precursors of AICD, that is, released in the cytoplasm
by γ-secretase cleavage [40, 41]. While C83 and C99 are
membrane-bound fragments of APP, the soluble N-terminal
fragmentofAPP,sAPP,generatedbyα/β-secretasecleavageis
released in the extracellular environment. In SH-SY5Y cells,
the β-secretase cleavage occurs to a much lower extent than
α-secretase cleavage. Therefore, the majority of the luciferase
signal observed is due to AICD-Gal4 generated from γ-
secretase cleavage of C83-Gal4. If the AICD-Gal4 levels are
increased, as measured by luciferase and Western blot, then
the levels of its precursor C83-Gal4 should also be increased.
We then tested the hypothesis that C83-Gal4 and sAPP
levels are increased by TrkB FL overexpression and decreased
by TrkB SHC. To aid detection of C83-Gal4 we treated cells
with the γ-secretase inhibitor L-685,485. We did not detect
ad i ﬀerence in C83-Gal4 levels among the cells transfected
with the diﬀerent TrkB isoforms (Figure 5(c)). Surprisingly,
TrkBFLdecreasedsAPPlevelscomparedtoTrkBT(P = .01).
TrkB SHC showed a nonsigniﬁcant diﬀerence in sAPP levels
compared to TrkB T (Figure 5(d)).
3.6. BDNF Treatment of TrkB Isoforms Does Not Signiﬁcantly
Alter Their Eﬀects on APP Metabolism. All three TrkB8 International Journal of Alzheimer’s Disease
isoforms studied here are capable of binding BDNF [12].
Moreover, it has been previously shown that TrkB FL BDNF-
mediated intra-cellular signaling can alter APP metabolism
[14–17]. We hypothesized that application of exogenous
BDNF would stimulate the TrkB FL-mediated eﬀects on
APP FL and proteolytic products levels. We then tested this
hypothesis applying BDNF to cells transfected with TrkB
isoforms and measured the levels of APP FL by Western blot.
We found that short term (10 minutes) BDNF application
increases APP FL levels in cells transfected with the TrkB
T or TrkB SHC isoforms and to a greater degree in cells
that had been transfected with TrkB FL (Figure 6). Twenty-
four hour BDNF treatment of TrkB FL transfected cells did
not further increase APP FL levels compared to short-term
BDNF treatment.
3.7. Cotransfection of the TrkB Isoforms Modulates TrkB FL-
Mediated Eﬀects on APP Metabolism. It has been previously
shown that TrkB T has a dominant negative eﬀect on TrkB
FL [42]. We hypothesized that cotransfection of TrkB T
with TrkB FL would eliminate the TrkB FL eﬀects on APP
metabolism observed when we transfect TrkB FL alone.
Moreover we hypothesized that cotransfection of the TrkB
SHC with TrkB FL would also have dominant negative eﬀect
on TrkB FL. Finally we hypothesized that cotransfection
of TrkB FL with TrkB Y515F or TrkB Y816F would not
signiﬁcantly alter the eﬀects seen on APP since they seem
to be primarily mediated by the tyrosine kinase domain
and not by the SHC-binding domain. For this reason we
also hypothesized that cotransfection of TrkB FL with TrkB
K571M (TrkB FL/K571M) would have the same eﬀect as the
cotransfection of TrkB FL and TrkB T (TrkB FL/T).
Consistent with our hypothesis, TrkB FL/T cotransfec-
tion did not increase APP FL levels, nor did cotransfection
of TrkB FL/K571M, the tyrosine kinase inactive mutant
(Figure 7). Also, as expected, there was very little diﬀerence
between the APP FL levels in cells transfected with TrkB
FL/Y515F, TrkB FL/Y816F, and TrkB FL/FL. Surprisingly,
cotransfection of TrkB FL/SHC increased APP FL levels
compared to TrkB FL/T cotransfection but not compared to
TrkB FL/FL (Figure 7).
We also hypothesized that BDNF treatment of the
cotransfected cells would aﬀect the transfected isoforms
mediated eﬀects on APP. Surprisingly BDNF treatment did
not signiﬁcantly alter these eﬀects of the cotransfected TrkB
receptors.
In summary, both truncated isoforms were able to
decreaseAPPFLlevelscomparedtoTrkBFL/FLtransfection;
TrkB T to a greater extent than TrkB SHC. The tyrosine
kinase inactive receptor decreased APP FL levels to the same
extent of TrkB FL/T cotransfection while TrkB FL/Y515F and
TrkB FL/Y816F cotransfection did not alter APP FL levels
compared to TrkB FL/FL.
4. Discussion
We investigated the role of the TrkB isoforms on APP
metabolism in SH-SY5Y cells overexpressing an APP-Gal4
fusion protein that can transactivate a luciferase reporter
gene [35]. This system monitors changes in APP metabolism
that are reﬂected in altered AICD-mediated transcription of
the luciferase gene [35].
We found that knockdown of all TrkB isoforms in SH-
SY5Y-APP-Gal4 cells caused a decrease in AICD-mediated
luciferase activity. This decrease is probably due to a
decrease in APP levels observed in cells with NTRK2 knock-
down. We hypothesize that decreased APP levels in this
system are mainly due to increased APP degradation caused
by altered traﬃcking in absence of TrkB. Transcriptional
downregulationofAPPmightbepartiallyresponsibleforthe
decreased signal observed in the Western Blot but that is only
possible for the endogenous APP. Because the endogenous
APP gene is under the physiologic transcriptional regulation,
while the APP-Gal4 overexpressed is under CMV promoter
regulation.
Concomitant knockdown of the TrkB FL and SHC
isoforms lead to cell death, and this is consistent with the
ﬁnding that TrkB T is one of the causes of neuronal death
in a mouse model of trisomy 21 [43].
To discriminate between the eﬀects of the diﬀerent
isoforms, we overexpressed one isoform at a time and
measuredtheresultingAICD-mediatedluciferaseactivity.As
a control we employed a GFP expression vector (GFP-F) that
includes a farnesylation sequence that targets GFP to the cell
membrane. This is a better control for a membrane-bound
receptorthanacytoplasmaticGFP.Interestingly,weobserved
isoform speciﬁc eﬀects. TrkB FL increased luciferase activity
while no diﬀerence was observed between TrkB T and GFP-
F control transfected cells. TrkB SHC induced a decrease in
AICD-mediated luciferase activity. We hypothesize that the
decrease in AICD-mediated luciferase activity induced by
TrkB SHC might be mediated by binding of SHC adaptor
proteins. Binding of adaptor proteins to TrkB and possibly
to APP, might decrease the endocytosis of APP decreasing
its β-secretase cleavage [44]. The luciferase assay described
here has been found to be particularly sensitive in detecting
decreased β-secretase processing [45] and that can be the
cause of the decrease in luciferase activity that we observe,
at least with cotransfection of the TrkB SHC isoform.
Our data demonstrates diﬀerential eﬀects of the TrkB
isoforms on AICD-mediated transcription showing that
TrkBSHCbehavesdiﬀerentlyfrombothTrkBFLandTrkBT.
It has been previously demonstrated that BDNF application
does not improve the cognitive function in a trisomy 21
mouse model because TrkB T is upregulated [43, 46].
Therefore, a better understanding of the individual TrkB
isoformsandtheirsignalingrolewillimprovethetherapeutic
potential of BDNF or BDNF agonists.
Experimentally, we found that the detected protein levels
of TrkB FL were much lower than TrkB T and TrkB SHC lev-
els.Wecanexcludeeﬀectsduetoplasmidcopynumberinthe
cells since we used equimolar amounts of plasmid DNA that
account for diﬀerences in plasmid size. We can also exclude
diﬀerences in transcription levels due to plasmid promoters
since the TrkB SHC vector was generated by mutagenesis of
the TrkB FL vector. The diﬀerence in expression levels of the
TrkB isoforms is highly reproducible suggesting that thereInternational Journal of Alzheimer’s Disease 9
might be a tight regulation of TrkB FL expression levels.
TrkB FL is stored in intracellular vesicles that rapidly fuse
to the cell membrane upon BDNF stimulation of the cells
[37]. This causes a fast BDNF-mediated phosphorylation
of the receptor and initiates intracellular signaling [47].
After this spike of activity TrkB/BDNF complexes are rapidly
endocytosed and degraded [48]. High TrkB FL expression
levels increase malignancy in neuroblastomas reinforcing the
idea that regulatory mechanisms of TrkB expression and
signaling are necessary to maintain homeostasis [49, 50].
TrkB FL expression is also decreased by chronic BDNF
stimulation of H4 neuroblastoma cells while TrkB T levels
remain constant [51]. We therefore hypothesize that in our
model system, TrkB FL levels are controlled by mechanisms
that cannot be overcome by TrkB FL overexpression and that
BDNF expressed by the cell line might be one of the causes of
this downregulation.
To determine which TrkB functional domain and sig-
naling pathway was mediating the TrkB mediate eﬀects,
we overexpressed the mutant TrkB isoforms and monitored
AICD-mediated luciferase activity. The observed TrkB FL-
mediated increase in luciferase activity was suppressed by
either inactivating the tyrosine kinase activity (K571M) or
mutating the PLC-γ-binding site (Y816F). We hypothesize
that the PLC-γ eﬀect is due to lack of PLC-γ activation which
produces DAG (Diacyl Glycerol), an activator of PKC, a
protein that mediates ADAM10 activation [52]. The fact that
there is a diﬀerence between the TrkB K571M mutant and
the TrkB Y816F PLC-γ-binding site mutant suggests both of
these functional domains and their associated pathways can
regulate APP metabolism.
The SHC-binding site on the TrkB FL receptor did
not seem to be involved in mediating increased AICD-
mediated luciferase activity since the TrkB Y515F mutant
did not diﬀer from the TrkB FL isoform in increasing
AICD-mediated luciferase activity. Also the AICD-mediated
luciferase signal in cells transfected with the double mutant
TrkB K571M/Y515F did not diﬀer from the cells transfected
with the TrKB K571M mutant suggesting that there is
no additive eﬀect in eliminating both signaling pathways.
This does not completely exclude a role for the SHC-
binding domain. In fact, the binding of SHC might occur
more eﬃciently when the site is phosphorylated so that
when phosphorylation is prevented the small change in
luciferasesignalisnotdetectableinourexperimentalsystem.
Supporting this hypothesis is a nonsigniﬁcant decrease of
AICD-mediated activity caused by the TrkB Y515F mutant
compared to TrkB FL.
We observe a signiﬁcant eﬀect when the TrkB SHC
isoform is mutated to eliminate SHC-binding. This mutant
induces the same luciferase activity signal of the TrkB T.
This ﬁnding suggests that binding of SHC to the TrkB SHC
isoform might mediate signaling pathways independently of
phosphorylation.Importantly,wedemonstratethatthereisa
diﬀerence in signal transduction between the two truncated
TrkB isoforms and that they act on APP-mediated tran-
scription. Moreover, we identify the SHC-binding domain
as responsible for the diﬀerence in signaling mechanism
between TrkB T and SHC. Mutation of the binding site for
SHC adaptor proteins on the truncated TrkB SHC isoform
increases AICD-mediated luciferase signal, while the same
SHC site on the TrkB FL is not responsible for the observed
changes in luciferase activity. This contrasting result suggests
that interaction between the same proteins and speciﬁc TrkB
isoforms mediates diﬀerent signaling pathways.
The cell line used, SH-SY5Y, expresses basal levels of
TrkB receptors and BDNF [31], the endogenously expressed
BDNF can promote dimerization and activation of the
overexpressed receptors. Also, BDNF independent activation
of TrkB FL receptors has been previously demonstrated
[53] and we hypothesize that both BDNF independent and
dependent activation coexist in our experimental system.
Endogenous TrkB receptors might also be upregulated or
downregulated in response to exogenous TrkB expression.
To assess the eﬀect of BDNF-dependent activation we
added exogenous BDNF to the transfected cells. BDNF
is hypothesized to activate the receptors by mediating
their dimerization [12]. In our experimental system BDNF
treatment did not signiﬁcantly alter the eﬀects of the TrkB
isoform overexpression on APP FL levels. It has been
observed before that TrkB FL overexpression can cause
receptor autoactivation [53]. Our data suggests that a similar
mechanism occurs in our experimental system. The close
proximity of the overexpressed receptors on the membrane
probably allows dimerization and activation of the receptors
independentlyfromBDNFsothatevenwhenBDNFisadded
to the system any additional eﬀect on TrkB activation is not
detectable.
We mentioned above that SH-SY5Y cells express basal
levels of the TrkB receptors. To investigate the role of TrkB
isoforms interaction on TrkB FL-mediated signaling, we
coexpressed exogenous TrkB FL with truncated isoforms and
mutated variants. Cotransfection of the TrkB FL with the
truncatedTandSHCisoformsorthetyrosinekinaseinactive
mutant abrogated the increase in APP FL levels induced
by TrkB FL. Interestingly TrkB FL/SHC cotransfection had
higher APP FL levels than TrkB FL/T cotransfection. This
points to a possible diﬀerence between the two TrkB
truncated isoforms in the regulation of the TrkB FL catalytic
receptor. The fact that in the cotransfection experiments
TrkB FL/SHC showed increased APP FL levels compared to
TrkB FL/T also suggests that SHC-binding to this isoform
might occur more eﬃciently when TrkB FL and TrkB
SHC interact, maybe causing phosphorylation on the SHC-
binding site. Cotransfection of TrkB FL/Y515F had similar
eﬀects on APP FL to TrkB FL/FL but was less eﬀective
in inducing an increase in APP FL levels. TrkB FL/Y816F
cotransfection was indistinguishable from TrkB FL single
transfection suggesting that PLC-γ signaling is not involved
in determining APP FL levels. BDNF treatment of the
cotransfected cells seemed to accentuate the eﬀect of TrkB FL
on APP FL levels. For example, it increased APP FL in cells
cotransfected with TrkB FL/T but not in cells cotransfected
with TrkB FL/K571M. On the contrary, TrkB FL/Y515F
cotransfection seemed to cause lower APP FL levels when
BDNF was applied. It is intriguing to think that when all
TrkB isoforms are expressed in the cells, as should be the case
in our model, BDNF promotes homodimerization versus10 International Journal of Alzheimer’s Disease
heterodimerization. The issue of preferential homo- versus
heterointeraction of TrkB isoforms has not been investigated
so far and it would be important to address.
5. Conclusions
This work demonstrates that truncated TrkB isoforms aﬀect
APPprocessingandtranscriptionalsignalingdiﬀerentlythan
full-length TrkB. Not only do the truncated isoforms have a
diﬀerenteﬀectswhentransfectedalone,theywerealsoableto
modify the TrkB FL eﬀects when co-transected with it. These
ﬁndings point to the possible roles of the TrkB isoforms in
the pathogenesis of AD. In fact all the isoforms are present
on neurons and other cell types of the CNS. The proportion
of TrkB FL to TrkB T and TrkB SHC is then important
in determining the eﬀect on TrkB signal transduction and
APP metabolism. Since all the isoforms bind BDNF in the
extracellulardomain,atherapeuticapproachthatusesBDNF
biomimetic drugs might not be as eﬀective as if only TrkB
FL was expressed. In fact, expression of truncated isoforms
could scavenge the drugs, decrease the beneﬁt of engaging
TrkB FL triggered pathways, and also inhibit the TrkB FL
eﬀects. Depending on the relative amounts of the TrkB
receptors on the cells, BDNF-mimetic drugs could cause an
overall worsening of the conditions [46] by, for example,
increasingtheinﬂammatoryresponse.Itwillbeimportantin
the future to dissect the contributions of the TrkB isoforms
toBDNF-dependentand-independentsignalingpathwaysin
the context of AD to better understand which isoforms and
pathways are beneﬁcial and which ones are detrimental.
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